CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28
Takeda Pharmaceutical Co (NYSE: TAK ) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate.
Takeda Pharmaceutical Co (NYSE: TAK ) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate.
Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate.